S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
TRDA · Entrada Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Entrada Therapeutics Inc (TRDA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$4.63
-0.35
(-6.93%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.63
$4.61
$4.98
52-WEEK RANGE
$4.63
$4.11
$16.45
What's happening
- TRDA is down 6.93% today, trading at $4.63. — Live quote
- Volume today (26,835) is well below its 3-month average of 360,520. (Finnhub fundamentals)
- Reports earnings on 2026-11-10 (before market open), 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.01 actual vs. $-1.07 estimated (+5.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 7
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TRDA
-51.46%
vs S&P 500
-64.24%
1-YEAR RETURN
TRDA
-20.16%
vs S&P 500
-34.72%
6-MONTH RETURN
TRDA
-63.20%
3-MONTH RETURN
TRDA
-22.76%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.01
Est. $-1.07
BEAT +5.7%
2026-04-26 (Q1 2026)
$-0.95
Est. $-1.06
BEAT +10.2%
2026-01-26 (Q4 2025)
$-0.94
Est. $-1.17
BEAT +19.9%
2025-10-26 (Q3 2025)
$-1.06
Est. $-0.96
MISS -10.6%
Valuation Measures & Ratios
Enterprise Value4$81.8M
Forward P/E5—
PEG Ratio6-0.01
Price / Sales (TTM1)38.64
Price / Book71.22
EV4 / Revenue17.45
EV4 / EBITDA11.48
Profit Margin-3537.73%
Operating Margin-3767.07%
Return on Equity (ROE8)-57.61%
Return on Assets (ROA9)-46.54%
Avg Volume (3M)360,520
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $312.0M | $528.2M | $240.7M | $278.1M | $373.4M |
| P/E | -1.84 | -3.66 | -2.03 | -14.30 | 7.92 |
| Price/Sales | 58.47 | 21.13 | 5.51 | 2.03 | 1.93 |
| Price/Book | 1.34 | 1.95 | 0.71 | 0.73 | 0.89 |
| EV/Revenue | 39.87 | 18.07 | 3.37 | 1.50 | 1.58 |
| ROE | -72.71% | -53.28% | -34.81% | -5.13% | 11.30% |
| ROA | -56.78% | -43.01% | -28.73% | -4.33% | 9.69% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,989,455
Change from Prior Settlement+8.94%
% of Float—
Days to Cover (Short Ratio)9.86
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -54.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -3537.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -20.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TRDA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $898.0K | $875.0K | $1.6M | $1.9M | $20.6M | $19.6M | $94.7M | $59.1M |
| Operating income | -$45.0M | -$42.3M | -$47.1M | -$46.8M | -$21.8M | -$21.7M | $53.4M | $21.1M |
| Net income | -$42.8M | -$39.7M | -$44.1M | -$43.1M | -$17.3M | -$14.0M | $55.0M | $23.5M |
| EPS (diluted) | $-1.01 | $-0.95 | $-1.06 | $-1.04 | $-0.42 | $-0.35 | $1.55 | $0.68 |
| EPS (basic) | $-1.01 | $-0.95 | $-1.06 | $-1.04 | $-0.42 | $-0.35 | $1.61 | $0.70 |
| Operating margin | -$5.0K | -$4.8K | -$2.9K | -$2.4K | -$106 | -$111 | $56 | $36 |
| Net margin | -$4.8K | -$4.5K | -$2.7K | -$2.2K | -$84 | -$72 | $58 | $40 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $298.9M | $335.5M | $377.4M | $412.9M | $448.8M | $486.5M | $526.3M | $554.6M |
| Total liabilities | $65.5M | $64.7M | $71.2M | $72.2M | $69.3M | $69.2M | $97.6M | $132.1M |
| Stockholders' equity | $233.4M | $270.9M | $306.1M | $340.7M | $379.5M | $417.3M | $428.7M | $422.4M |
| Total current assets | $232.7M | $266.9M | $306.3M | $338.3M | $369.1M | $403.2M | $440.0M | $465.3M |
| Total current liabilities | $21.4M | $19.2M | $24.5M | $24.0M | $19.8M | $18.4M | $39.5M | $70.6M |
| Cash & equivalents | $99.3M | $76.4M | $90.4M | $93.3M | $72.5M | $67.8M | $101.2M | $78.0M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $5.7M | $6.5M | $7.3M | $8.4M | $9.8M | $10.7M | $10.9M | $10.8M |
| Other non-current assets | $118.0K | $90.0K | $70.0K | $163.0K | $199.0K | $239.0K | $284.0K | $746.0K |
| Accounts payable | $3.7M | $2.9M | $2.3M | $3.2M | $1.9M | $2.2M | $4.3M | $1.3M |
| Accrued liabilities | $13.0M | $11.7M | $17.7M | $15.5M | $11.8M | $7.6M | $13.3M | $13.4M |
| Deferred revenue (current) | $173.0K | $254.0K | $342.0K | $351.0K | $689.0K | $1.4M | $13.7M | $45.9M |
| Common stock & paid-in capital | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K |
| Retained earnings | -$355.6M | -$312.8M | -$273.1M | -$233.9M | -$189.8M | -$146.7M | -$129.3M | -$130.5M |
| Accumulated other comprehensive income (loss) | $66.0K | $246.0K | $652.0K | $621.0K | $400.0K | $437.0K | -$43.0K | $972.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.5M | -$41.7M | -$32.2M | -$28.3M | -$29.5M | -$38.5M | -$31.6M | -$24.3M |
| Investing cash flow | $54.9M | $27.0M | $29.1M | $49.1M | $33.8M | $4.8M | $53.4M | -$82.9M |
| Financing cash flow | $350.0K | $100.0K | $192.0K | $8.0K | $337.0K | $350.0K | $1.4M | -$11.0K |
| Free cash flow | -$32.5M | -$41.7M | -$32.0M | -$28.1M | -$29.8M | -$39.7M | -$32.2M | -$24.9M |
| Capital expenditures | $11.0K | $44.0K | -$207.0K | -$171.0K | $275.0K | $1.1M | $635.0K | $639.0K |
| Share-based compensation | $5.2M | $4.7M | $4.4M | $5.1M | $5.0M | $5.1M | $4.7M | $4.9M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Purchases of investments | $3.9M | $11.8M | $18.5M | $26.6M | $16.6M | $80.0M | $64.5M | $165.6M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | — | — |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M | -$51.2M |
| EPS (diluted) | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 |
| EPS (basic) | $-3.47 | $1.76 | $-0.20 | $-3.02 | $-8.16 |
| Operating margin | -$621 | $22 | -$2 | — | — |
| Net margin | -$565 | $31 | -$5 | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M |
| Stockholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M |
| Total current assets | $306.3M | $440.0M | $369.8M | $209.9M | $298.7M |
| Total current liabilities | $24.5M | $39.5M | $158.8M | $22.0M | $6.7M |
| Cash & equivalents | $90.4M | $101.2M | $67.6M | $45.2M | $291.1M |
| Property, plant & equipment | $7.3M | $10.9M | $11.2M | $7.7M | $6.3M |
| Other non-current assets | $70.0K | $284.0K | $2.8M | $5.2M | $872.0K |
| Accounts payable | $2.3M | $4.3M | $3.3M | $6.0M | $706.0K |
| Accrued liabilities | $17.7M | $13.3M | $11.3M | $7.6M | $6.0M |
| Deferred revenue (current) | $342.0K | $13.7M | $132.3M | $0 | — |
| Common stock & paid-in capital | $4.0K | $4.0K | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$273.1M | -$129.3M | -$195.0M | -$188.3M | -$93.7M |
| Accumulated other comprehensive income (loss) | $652.0K | -$43.0K | $195.0K | -$2.1M | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M |
| Investing cash flow | $116.8M | -$27.8M | -$138.4M | -$148.7M | -$4.6M |
| Financing cash flow | $887.0K | $103.0M | $21.0M | $479.0K | $307.5M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M |
| Capital expenditures | $1.0M | $3.2M | $5.6M | $2.9M | $4.6M |
| Share-based compensation | $19.6M | $17.9M | $13.1M | $9.9M | $2.5M |
| Deferred income taxes | $0 | $0 | $0 | $0 | — |
| Purchases of investments | $141.6M | $437.7M | $407.2M | $222.0M | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TRDA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-04 to 2026-09-09
Recent transactions
- Insiders have net sold 1,478,815 shares over the last 182 days, across 1 purchase and 35 sales.
- Most recent: MPM BIOVENTURES 2018, L.P. (Reporting person) — Open market sale of 28,837 shares on 2026-09-09.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)5,000 sh(1 txns)
Sales (open market)1,483,815 sh(35 txns)
Net Shares-1,478,815
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 2026-09-09 | 28,837 |
| MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 2026-09-09 | 28,837 |
| Doshi Dipal | CEO | Tax withholding | 2026-09-02 | 8,724 |
| Dowden Nathan J | President & COO | Tax withholding | 2026-09-02 | 2,528 |
| Sethuraman Natarajan | President, Research & Develop. | Tax withholding | 2026-09-02 | 2,079 |
| WENTWORTH KORY JAMES | Chief Financial Officer | Tax withholding | 2026-09-02 | 1,733 |
| PARMAR KUSH | Reporting person | Open market sale | 2026-08-10 | 92,444 |
| 5AM Ventures V, L.P. | Reporting person | Open market sale | 2026-08-07 | 52,317 |
| Zeiher Bernhardt G | Director | Open market purchase | 2026-05-20 | 5,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-09 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 28,837 | $7.13 |
| 2026-09-09 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 28,837 | $7.13 |
| 2026-09-08 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 192,500 | $7.41 |
| 2026-09-08 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 192,500 | $7.41 |
| 2026-09-04 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 38,500 | $7.11 |
| 2026-09-04 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 38,500 | $7.11 |
| 2026-09-03 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 32,263 | $7.17 |
| 2026-09-03 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 32,263 | $7.17 |
| 2026-09-02 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 25,131 | $7.19 |
| 2026-09-02 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 25,131 | $7.19 |
| 2026-09-02 | Doshi Dipal | CEO | Tax withholding | 8,724 | $7.14 |
| 2026-09-02 | Dowden Nathan J | President & COO | Tax withholding | 2,528 | $7.14 |
| 2026-09-02 | Sethuraman Natarajan | President, Research & Develop. | Tax withholding | 2,079 | $7.14 |
| 2026-09-02 | WENTWORTH KORY JAMES | Chief Financial Officer | Tax withholding | 1,733 | $7.14 |
| 2026-09-01 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 29,088 | $7.06 |
| 2026-09-01 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 29,088 | $7.06 |
| 2026-08-31 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 44,259 | $6.99 |
| 2026-08-31 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 44,259 | $6.99 |
| 2026-08-28 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 3,733 | $7.01 |
| 2026-08-28 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 3,733 | $7.01 |
| 2026-08-27 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 38,922 | $7.20 |
| 2026-08-27 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 38,922 | $7.20 |
| 2026-08-26 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 14,569 | $7.06 |
| 2026-08-26 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 14,569 | $7.06 |
| 2026-08-25 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 26,522 | $7.54 |
| 2026-08-25 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 26,522 | $7.54 |
| 2026-08-24 | MPM BioVentures 2014, L.P. | Reporting person | Open market sale | 21,623 | $7.34 |
| 2026-08-24 | MPM BIOVENTURES 2018, L.P. | Reporting person | Open market sale | 21,623 | $7.34 |
| 2026-08-10 | PARMAR KUSH | Reporting person | Open market sale | 92,444 | $7.00 |
| 2026-08-07 | PARMAR KUSH | Reporting person | Open market sale | 52,317 | $6.85 |
| 2026-08-07 | 5AM Ventures V, L.P. | Reporting person | Open market sale | 52,317 | $6.85 |
| 2026-08-06 | PARMAR KUSH | Reporting person | Open market sale | 10,494 | $7.00 |
| 2026-08-06 | 5AM Ventures V, L.P. | Reporting person | Open market sale | 10,494 | $7.00 |
| 2026-07-31 | 5AM Ventures V, L.P. | Reporting person | Open market sale | 1,718 | $6.85 |
| 2026-07-31 | PARMAR KUSH | Reporting person | Open market sale | 1,718 | $6.85 |
| 2026-07-30 | 5AM Ventures V, L.P. | Reporting person | Open market sale | 114,756 | $6.93 |
| 2026-07-30 | PARMAR KUSH | Reporting person | Open market sale | 114,756 | $6.93 |
| 2026-05-20 | Zeiher Bernhardt G | Director | Open market purchase | 5,000 | $5.86 |
| 2026-05-04 | Sethuraman Natarajan | President, Research & Develop. | Open market sale | 25,907 | $15.39 |
| 2026-05-04 | Dowden Nathan J | President & COO | Option exercise | 15,000 | $1.74 |
| 2026-05-04 | Dowden Nathan J | President & COO | Open market sale | 15,000 | $15.33 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:39 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-08-31 | 4 | 2026-08-27 | View on SEC.gov → |
| 2026-08-31 | 4 | 2026-08-27 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-24 | View on SEC.gov → |
Recent news
Headlines about TRDA (Entrada Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Entrada Therapeutics names Linea Aspesi as chief people officer By Investing.com
Investing.com Australia · 2026-10-21 -
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Yahoo · 2026-10-21 -
Why Did Entrada Therapeutics (NASDAQ:TRDA) Surge 10.07% on Monday? The Catalyst, the Fundamentals and What Comes Next
kalkine.ca · 2026-10-19 -
What's Going On With Entrada Therapeutics Stock Wednesday?
Yahoo · 2026-10-14 -
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Yahoo · 2026-10-14 -
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Yahoo · 2026-10-14 -
Entrada Therapeutics Announces Independent Data Monitoring Committee Review Of All Available Safety And PK Data From The Eight Participants Enrolled In Cohort 2 Of The Double-Blind, Placebo-Controlled, Multiple Ascending
Benzinga · 2026-10-14 -
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
SeekingAlpha · 2026-10-10
No headlines in this category right now — try “All”.